Navigation Links
Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
Date:10/2/2008

us, even life-threatening adverse reactions. In contrast, Circassia's anti-allergy technology has the potential to provide effective but shorter treatments, while minimizing the threat of severe side-effects."

About Circassia

Circassia is a specialty biopharmaceutical company focused on the fields of allergy and critical care. The company has a highly experienced management team with a proven track record in product development and commercialization, and having successfully completed two fundraising rounds is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune. The company is also developing its ToleroTrans organ anti-rejection technology, which uses a similar approach to down-regulate immune responses in transplant patients.

Circassia's anti-allergy products offer potential important clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe and the market for current treatments is approximately $12 billion per year. The prevalence of cat allergies is also high, with 1-in-6 Americans and nearly 10% of Europeans suffering from the condition.

For more information please visit http://www.circassia.co.uk.


'/>"/>
SOURCE Circassia Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
2. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
3. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
4. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
5. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
6. Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
7. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
8. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
9. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
10. Isis Initiates Clinical Trial of CRP Drug
11. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... 19, 2014 Aufgrund der ... äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die ... verfügbar unter pharmaserialisation.com , zeigt die Serialisierungsanforderungen ... in Kraft treten. Für international tätige ... um das "ob", sondern darum, "wann" sie die ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. ... Inc. (PGDx), a provider of advanced cancer ... Medicines , a leader in discovering and developing ... today disclosed the first-ever comprehensive genomic study of ... deadly cancer of the female reproductive system, also ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
(Date:9/19/2014)... 2014 BCC Research reveals in its ... MARKETS , the global market for human antifungal therapeutics ... 2018, with a five-year compound annual growth rate (CAGR) ... at a steady 3.8% CAGR. , Given the current ... coupled with the incidence of increasing mortality and the ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Ticket Down ... tickets for her 2015 “Honeymoon” Tour. This popular ... for additional savings at the checkout. , Ariana Grande 2015 ... (Independence Event Center) , Feb. 28, 2015: Milwaukee, WI (BMO ... (Xcel Energy Center) , March 03, 2015: Chicago, IL (Allstate ...
(Date:9/19/2014)... An ultrasensitive biosensor made from the wonder material graphene ... increased risk of developing cancer. , The biosensor ... more sensitive than bioassay tests currently in use, and ... minutes, opening up the possibility of a rapid, point-of-care ... presented today, 19 September, in IOP Publishing,s journal ...
(Date:9/19/2014)... Follow us on LinkedIn ... detection and quantification of the presence of antigens ... steady expansion in immunodiagnostics and technological advancements in ... market has evolved remarkably well over the years. ... cardio-vascular ailments, infectious diseases, allergy and cancer, continue ...
(Date:9/19/2014)... 19, 2014 Recent financial data ... industry increased their sales by 7% in the last ... trucking industry can be used as a bellwether to ... whole. This data has been proven to show trends ... freight transportation. Other non-trucking data is largely influenced by ...
Breaking Medicine News(10 mins):Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 3Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 2Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 3Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 4Health News:Graphene sensor tracks down cancer biomarkers 2Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 4Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 3
... Institute along with the Hong Kong Cleft Lip and Palate ... for congenital facial deformities in the city of Chennai//. The ... Samman, Director of the Hong Kong Cleft Lip & Palate ... Surgeons. , ,The center has tied up with Hong ...
... the 'Bambach Saddle Seat' invented by Australian therapist Mary Gale, ... ,The chair, which is priced at 399 pounds, was found ... positions the pelvis correctly. ,Each person tested was ... backwards slightly and given a task to perform. This was ...
... blamed for obesity by a study in Florida. The study was ... fructose present in fruits//, honey and other natural sources might be ... that Fructose makes beleive that the subject is hungrier than actually ... ,The study in animals have revealed that fructose has a ...
... persistent pain may be increased by an inflamed injury, according ... even after it has disappeared//. Several million Canadians are reported ... has published the study. The NR2B proteins in mice are ... to imprint upon the brain a painful response even when ...
... 2025, the number of people in Britain over the age ... pensions and pensioner spending power will increase. Answers to problems//, ... ,In a move to address the issues of ageing ... our lives, the Economic and Social Research Council (ESRC) is ...
... ,The disabled, homeless man who died on ... sub-zero temperatures had refused the help of paramedics, say ... the paramedics on Saturday night did actually respond to ... and the patient clearly refused any assistance from the ...
Cached Medicine News:Health News:New Chair Invented To Relieve Backache 2Health News:Fructose is a tricker and not all that sweet! 2Health News:ESRC offers new dynamics for old in UK 2Health News:ESRC offers new dynamics for old in UK 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: